Thursday, November 19, 2015 Daily Archives

Refolding of Biopharmaceuticals by FOLDTEC: A Case Study on Recombinant Thrombin

This webcast features: Dr. Andreas Anton, Director Bioprocess Development and Dr. Sebastian Schuck, Senior Manager Business Development, Wacker Biotech While WACKER’s own technology ESETEC® has proven highly efficient in producing soluble proteins and antibody fragments via secretion, poorly soluble substances form aggregated inclusion bodies within the cell, which contain incorrectly and/or incompletely folded target proteins. Recently Wacker Biotech introduced FOLDTEC®, its novel refolding technology for bioengineered pharmaceutical proteins. With this new technology, biopharmaceuticals that tend to aggregate can be efficiently…

Downstream Processing – Interview with Pete Gagnon

BioProcess International editor in chief Anne Montgomery spoke with Pete Gagnon, Group Manager, Downstream Processing, Bioprocessing Technology Institute, Singapore, at the BioProcess International Conference and Exposition in Boston, MA, October 2015. Sponsored by Click here to view the other videos in this series.

Downstream Processing – Interview with Giorgio Carta

BioProcess International editor in chief, Anne Montgomery, interviewed Giorgio Carta, Lawrence R. Quarles Professor, Department of Chemical Engineering, University of Virginia at the BioProcess International Conference and Exposition in Boston, MA, in October 2015. Sponsored by Click here to view the other videos in this series.

Increased Monoclonal Antibody Resolution with TSKgel® UP-SW3000 Columns

The antibody therapeutics market is enjoying high growth rates, the major areas of therapeutic application being cancer and immune/inflammation-related disorders including arthritis and multiple sclerosis. In 2013, six of the top ten best-selling global drug brands were monoclonal antibodies (mAbs) and more than 400 mAbs were in clinical trials. The characterization of these complex biomolecules is a major challenge in process monitoring and quality control. The main product characteristics to be monitored are aggregate and fragment content, glycosylation pattern and…

Downstream Processing – Interview with Dr. Carsten Voß

BioProcess International editor in chief Anne Montgomery spoke with Dr. Carsten Voß, application specialist, Process Chromatography, Bio-Rad Laboratories GmbH at the BioProcess International Conference and Exposition in Boston, MA, October 2015. Sponsored by Click here to view the other videos in this series.

A Fresh Approach to Process and Cost Efficiencies in Early Clinical and Biosimilars Production

This poster will introduce Praesto™ AC protein A resin and ProcessReady pre-packed columns from Purolite. Platform processes for MAbs manufacturing have long been used to save time and costs. The use of highly productive, cost- effective resins in such platforms can magnify these savings, and the addition of ready-to use formats can further enhance process efficiencies. Our approach is to maximize these efficiencies and cost savings in early clinical-phase production and in the manufacture of biosimilars by using stage-appropriate materials…